Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study
dc.contributor.author | ArdeshirRouhaniFard, Shirin | |
dc.contributor.author | Dinh, Paul C. | |
dc.contributor.author | Monahan, Patrick O. | |
dc.contributor.author | Fossa, Sophie D. | |
dc.contributor.author | Huddart, Robert | |
dc.contributor.author | Fung, Chunkit | |
dc.contributor.author | Song, Yiqing | |
dc.contributor.author | Feldman, Darren R. | |
dc.contributor.author | Hamilton, Robert J. | |
dc.contributor.author | Vaughn, David J. | |
dc.contributor.author | Martin, Neil E. | |
dc.contributor.author | Kollmannsberger, Christian | |
dc.contributor.author | Einhorn, Lawrence | |
dc.contributor.author | Kroenke, Kurt | |
dc.contributor.author | Travis, Lois B. | |
dc.contributor.department | Medicine, School of Medicine | |
dc.date.accessioned | 2023-04-13T16:00:12Z | |
dc.date.available | 2023-04-13T16:00:12Z | |
dc.date.issued | 2021-06 | |
dc.description.abstract | Background: This study examined sociodemographic factors, cisplatin-related adverse health outcomes (AHO), and cumulative burden of morbidity (CBMPt) scores associated with medication use for anxiety and/or depression in testicular cancer survivors (TCS). Methods: A total of 1,802 TCS who completed cisplatin-based chemotherapy ≥12 months previously completed questionnaires regarding sociodemographic features and cisplatin-related AHOs [hearing impairment, tinnitus, peripheral sensory neuropathy (PSN), and kidney disease]. A CBMPt score encompassed the number and severity of cisplatin-related AHOs. Multivariable logistic regression models assessed the relationship of individual AHOs and CBMPt with medication use for anxiety and/or depression. Results: A total of 151 TCS (8.4%) used medications for anxiety and/or depression. No cisplatin-related AHOs were reported by 511 (28.4%) participants, whereas 622 (34.5%), 334 (18.5%), 287 (15.9%), and 48 (2.7%), respectively, had very low, low, medium, and high CBMPt scores. In the multivariable model, higher CBMPt scores were significantly associated with medication use for anxiety and/or depression (P < 0.0001). In addition, tinnitus (P = 0.0009), PSN (P = 0.02), and having health insurance (P = 0.05) were significantly associated with greater use of these medications, whereas being employed (P = 0.0005) and vigorous physical activity (P = 0.01) were significantly associated with diminished use. Conclusions: TCS with higher CBMPt scores had a higher probability of using medications for anxiety and/or depression, and conversely, those who were employed and physically active tended to have reduced use of these medications. Impact: Healthcare providers should encourage TCS to increase physical activity to improve both physical and mental health. Rehabilitation programs should assess work-related skills and provide career development counseling/training. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | ArdeshirRouhaniFard S, Dinh PC, Monahan PO, et al. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1129-1138. doi:10.1158/1055-9965.EPI-20-1762 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/32385 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Association for Cancer Research | en_US |
dc.relation.isversionof | 10.1158/1055-9965.EPI-20-1762 | en_US |
dc.relation.journal | Cancer Epidemiology, Biomarkers & Prevention | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Anti-anxiety agents | en_US |
dc.subject | Anxiety | en_US |
dc.subject | Depression | en_US |
dc.subject | Hearing loss | en_US |
dc.subject | Kidney diseases | en_US |
dc.subject | Testicular neoplasms | en_US |
dc.subject | Tinnitus | en_US |
dc.title | Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study | en_US |
dc.type | Article | en_US |